Date: 2014-11-12
Type of information: R&D agreement
Compound:
Company: Medgenics (USA-Israel) The Children\'s Hospital of Philadelphia (USA - PA)
Therapeutic area: Genetic diseases - Pediatric diseases - Rare diseases
Type agreement: R&D
Action mechanism:
Disease: pediatric rare and orphan genetic diseases
Details: * On November 12, 2014, Medgenics announced a major research collaboration with The Children\'s Hospital of Philadelphia (CHOP) focused on pediatric rare and orphan genetic diseases. The goal of the collaboration is to accelerate the development of transformational new therapies for these underserved patients. The research collaboration will leverage the unique strengths of both organizations. The biobank at CHOP\'s Center for Applied Genomics (CAG) is home to one of the largest biorepositories of pediatric genetic data in the world. Access to the rich genetic information in the CAG biobank will uniquely enable CHOP and Medgenics researchers to work rapidly and efficiently to identify new rare and orphan disease targets and accelerate the development of novel therapies into clinical stage programs.
Financial terms: Under the terms of the agreements, Medgenics will pay $5 million to CHOP. Medgenics will have an exclusive license to use the rare and orphan disease samples at the CAG biobank for the purpose of developing and commercializing therapeutic treatments and diagnostic targets for rare and orphan diseases. CHOP will also receive milestone payments and low single-digit royalties on future sales from products developed from the collaboration, and Medgenics will sponsor further research at CHOP on rare and orphan diseases.
Latest news:
